Local heat application for the treatment of Buruli Ulcer: Results of a Phase II open label single center non comparative clinical trial

Clinical Infectious Diseases

Volumn 62, Issue 3, 2016, Pages 342-350

  Vogel, Moritz ^a   Bayi, Pierre F ^b   Ruf, Marie Thérèse ^c,d   Bratschi, Martin W ^c,d   Bolz, Miriam ^c,d   Um Boock, Alphonse ^b   Zwahlen, Marcel ^e   Pluschke, Gerd ^c,d   Junghanss, Thomas ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b FAIRMED   (Cameroon)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

Buruli ulcer; local thermotherapy; Mycobacterium ulcerans

Indexed keywords

ARTICLE; BURULI ULCER; CHILD; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTHERMIC THERAPY; LOCAL SKIN REACTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM ULCERANS; OPEN STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; WOUND CARE; WOUND CLOSURE; WOUND HEALING; ADVERSE EFFECTS; CAMEROON; CLINICAL TRIAL; COMPARATIVE STUDY; HEAT; PROCEDURES; THERMOTHERAPY;

BURULI ULCER; CAMEROON; CHILD; FEMALE; HOT TEMPERATURE; HUMANS; HYPERTHERMIA, INDUCED; MALE; TREATMENT OUTCOME;

EID: 84961861166     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ883     Document Type: Article

References (31)

1. Junghanss T, Johnson RC, Pluschke G. Mycobacterium ulcerans disease. In: Farrar J, Hotez PJ, Junghanss T, Kang G, Lalloo D, White N, eds. Manson s Tropical Diseases. 23rd ed. Philadelphia: Elsevier, 2014: 519-31
2. Bratschi MW, Bolz M, Minyem JC., et al. Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mape Basin of Cameroon. PLoS Negl Trop Dis 2013; 7: e2252
3. World Health Organization. Treatment of Mycobacterium ulcerans disease (Buruli ulcer). Geneva: World Health Organization, 2012
4. Asiedu K, Etuaful S. Socioeconomic implications of Buruli ulcer in Ghana: a threeyear review. Am J Trop Med Hyg 1998; 59: 1015-22
5. Agbenorku P, Edusei A, Agbenorku M., et al. Buruli-ulcer induced disability in Ghana: a study at Apromase in the Ashanti region. Plast Surg Int 2012: 752749
6. George KM, Chatterjee D, Gunawardana G., et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999; 283: 854-7
7. Demangel C, Stinear TP, Cole ST. Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol 2009; 7: 50-60
8. World Health Organization. Global Buruli Ulcer Initiative. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). Geneva: World Health Organization, 2004
9. NienhuisWA, Stienstra Y, ThompsonWA., et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010; 375: 664-72
10. Asiedu K, Raviglione MC, Scherpbier R, World Health Organization. Global Buruli Ulcer Initiative. Buruli ulcer: Mycobacterium ulcerans infection. Geneva: World Health Organization, 2000
11. Meyers WM, Shelly WM, Connor DH. Heat treatment of Mycobacterium ulcerans infections without surgical excision. Am J Trop Med Hyg 1974; 23: 924-9
12. Junghanss T, Um Boock A, Vogel M, Schuette D, Weinlaeder H, Pluschke G. Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLoS Negl Trop Dis 2009; 3: e380
13. Braxmeier S, Hellmann M, Beck A., et al. Phase change material for thermotherapy of Buruli ulcer: modelling as an aid to implementation. J Med Eng Technol 2009; 33: 559-66
14. Buntine J, Crofts K, World Health Organization. Global Buruli Ulcer Initiative. Buruli ulcer: management of Mycobacterium ulcerans disease: a manual for health care providers. Geneva: World Health Organization, 2001
15. Portaels F, Johnson P, Meyers WM, World Health Organization. Global Buruli Ulcer Initiative. Buruli ulcer: diagnosis of Mycobacterium ulcerans disease: a manual for health care providers. Geneva: World Health Organization, 2001
16. Lavender CJ, Fyfe JA. Direct detection of Mycobacterium ulcerans in clinical specimens and environmental samples. Methods Mol Biol 2013; 943: 201-16
17. BratschiMW, Bolz M, Grize L., et al. Primary cultivation: factors affecting contamination and Mycobacterium ulcerans growth after long turnover time of clinical specimens. BMC Infect Dis 2014; 14: 636
18. Collins TJ. ImageJ for microscopy. Biotechniques 2007; 43(1 suppl): 25-30
19. Valencia BM, Miller D, Witzig RS, Boggild AK, Llanos-Cuentas A. Novel low-cost thermotherapy for cutaneous leishmaniasis in Peru. PLoS Negl Trop Dis 2013; 7: e2196
20. Phillips RO, Sarfo FS, Abass MK., et al. Clinical and bacteriological efficacy of combination of rifampicin and streptomycin for 2 weeks followed by rifampicin and clarithromycin for 6 weeks for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 2014; 58: 1161-6
21. NienhuisWA, Stienstra Y, Abass KM., et al. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis 2012; 54: 519-26
22. Ruf MT, Chauty A, Adeye A., et al. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?. PLoS Negl Trop Dis 2011; 5: e1252
23. Beissner M, Piten E, Maman I., et al. Spontaneous clearance of a secondary Buruli ulcer lesion emerging ten months after completion of chemotherapy-A case report from Togo. PLoS Negl Trop Dis 2012; 6: e1747
24. Schutte D, Pluschke G. Immunosuppression and treatment-Associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). Expert Opin Biol Ther 2009; 9: 187-200
25. Kibadi K, Boelaert M, Fraga AG., et al. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis 2010; 4: e736
26. Debacker M, Aguiar J, Steunou C., et al. Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis 2004; 10: 1391-8
27. Portaels F, Aguiar J, Debacker M., et al. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 2004; 72: 62-5
28. Phanzu DM, Bafende EA, Dunda BK., et al. Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital in Bas-Congo, Democratic Republic of Congo, 2002-2004. Am J Trop Med Hyg 2006; 75: 311-4
29. Trellu LT, Nkemenang P, Bastard M., et al. Differential diagnoses of Buruli ulcer: Data from Akonolinga, Cameroon. In: WHO Meeting on Buruli ulcer, Control and Research 2015. Geneva, Switzerland: WHO Headquarters
30. Klis S, Stienstra Y, Phillips RO, Abass KM, Tuah W, Van Der Werf TS. Long term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial. PLoS Negl Trop Dis 2014; 8: e2739
31. Eddyani M, Lavender C, De Rijk WB., et al. Multicenter external quality assessment program for PCR detection of Mycobacterium ulcerans in clinical and environmental specimens. PLoS One 2014; 9: e89407